Drug Discovery World Asia 2012 - list of speakers

Dr. Sam Azoulay is the Senior Vice President, Medical & Development, of the Emerging Markets and Established Products Business Units for Pfizer Inc. Dr. Azoulay joined Pfizer as a result of the company’s acquisition of Parke Davis, Warner Lambert in 2000, where he had served as Development Site Head in Eastleigh, UK and Head of Cardiovascular...

Hans-Joachim Böhm is Global Head of Chemistry at Roche and Center Manager for the Roche Pharma Research and Early Development Site Basel. Prior to this, Hans-Joachim Böhm was President and Research Site Head of Roche Palo Alto from October 2006 to June 2008. Hans-Joachim Böhm also headed Non-clinical Development at Roche Basel from January 2005...

Andreas has been a memmber of the Bayer HealthCare Executive COmmittee as Head of Pharmaceuticals Reserch since February 2007. He has also been in charge of Research in the Animal Health Division since March 2011. Andreas has worked at various research institutes in Germany and USA prior to joining the industry. His scientific work has been...

Swaine Chen received his Ph.D. in Developmental Biology and an M.D. from Stanford University in 2004. He became interested in applying computational tools to infectious diseases during his post-doc in the lab of Scott Hultgren, Ph.D. at Washington University. Since 2010, he has been a Senior Research Scientist at the Genome Institute of...

Dr. Jiehao Chen pursued his PhD at the Department of Chemistry of the University of Minnesota and his postdoctoral studies at The Memorial Sloan-Kettering Cancer Center, New York, under the supervision of Professor Samuel Danishefsky. Then Dr. Chen joined Eli Lilly and Company where he did extensive research on drug discovery of small molecules...

Chih-Liang Chin, Ph.D. is Director and Site Lead Imaging, Translational Medicine Research Centre at Merck & Sharp Dohme, Singapore. In this role, Chih-Liang provides leadership and coordination for the development of translational imaging biomarker in nonhuman primate across various disease franchises. His team also supports the early stage...

Professor Ceri Davies graduated from the University of Bristol with a first class honours degree and PhD in pharmacology and ran an independent academic laboratory at the University of Edinburgh before leaving academia in 1998 to join the pharmaceutical industry at Organon Laboratories Scotland and subsequently SmithKline Beecham and...

Iman is a clinical Oncologist, earned her MD in Alexandria medical school in Egypt, and her PhD at the Imperial college, London, UK. She moved to the Pharmaceutical sector in 1998 and worked as a leader of oncology in GSK for 10 years, based in UK where she lead the clinical development of lapatinib, a dual tyrosine kinase inhibitor of HER2 and...

Professor Elliott trained as a Paediatrician at Adelaide University and entered Academia in 1962. He undertook research training in Denver and returned as a Senior Lecturer to Adelaide. He moved to New Zealand in 1970 to become the Foundation Professor, Department of Pediatrics at the University of Auckland, and in 1978 Professor of Child Health...

Martin Everett joined MerLion in 2005, initially as Head of Biological Sciences, becoming Head of Research in 2008. Before joining MerLion he worked at Glaxo SmithKline in the UK on anti-tubercular drug discovery and led a team performing automated high throughput screening of enzyme targets within the Molecular Screening department. Between...

Adam obtained his Ph.D. in the Department of Pathology at Case Western Reserve University (2004) in Cleveland, Ohio, where he studied strategies employed by Mycobacterium tuberculosis to evade detection of the CD4 T cell response. From there Adam joined the UCL Institute of Hepatology (2004-2006) at University College London as a research fellow...

Olivier Heudi obtained his diploma of advanced studies in physiology and pharmacology at Pasteur Institute Paris (France) in 1995 and his Ph.D. in life Sciences at the University of Angers France in 1999. He previously gained experience in the analytical field at GSK Stevenage (UK) where he has implemented LC-ICPMS and LC-MS/MS for the...

Pooja Jain currently works in the PharmaBioTech division at Elsevier and brings with her over 10 years of experience in the health science sector. After obtaining her Master’s degree from McGill University in Experimental Medicine in 2004, she worked in academia for 2 years in the field of telomerase research and then transitioned her career into...

BBRC is a BMS R&D center for Drug Discovery and Development in Bangalore, India with approximately 425 scientists. BBRC evolved from a simple outsourcing model started with Biocon in 1997 to a major strategic R&D site for BMS in emerging markets where new innovative medicines are discovered and developed for global diseases, such as...

Dr. Raj Kamboj is President of Novel Drug Discovery and Development at Lupin Ltd. After completing his Ph.D, he worked as a Research Scientist in Australia till 1986. Thereafter, he moved to Canada to join Allelix Biopharmaceuticals Inc./NPS Pharmaceuticals Inc., Toronto, as its Vice President and Chief Scientific Officer. At...

Shinichi Koizumi, Ph.D. has experience in drug discovery more than 20 years and is one of founders of RaQualia and currently serving as Head of Research and CSO. Before starting RaQualia Shinichi was responsible as Head of Biology in Pfizer Central Research Laboratories at Nagoya and contributed producing several development candidates in the...

Michel Liuzzi, Ph.D., has served as Director, Early Discovery Program at the Institut Pasteur Korea, Seoul (Korea) since January 2011. Prior to that, he was affiliated for 6 years with Idenix Pharmaceuticals Inc., Cambridge (USA) as Senior Director Virology. There he made substantial contributions to the HIV and HCV drug pipeline with the...

After receiving his Ph.D. and working in California’s biotech industry for 10 years, Dr. Ying Luo returned to China to found Shanghai Genomics as a new generation Chinese drug discovery company in 2001. He has led three Chinese National “863” Hi-Tech Development Projects in the field of drug target discovery and co-authored more than 35 research...

"Professor Alex Matter, M.D., is CEO of the Experimental Therapeutics Centre, A*STAR, Singapore, having spent five and a half years as Director of the Novartis Institute for Tropical Diseases (NITD), from October 2003 to February 2009. Prior to this role, Dr. Matter was Global Head of Oncology Research for Novartis Pharmaceuticals...

Atsushi Nagahisa, Ph.D., is a founder of RaQualia Pharma Inc. (RaQualia) and has served as President and Chief Executive Officer since the company’s launch in July 2008. He raised $111 million to start RaQualia and successfully completed IPO in July 2011 on the Osaka Securities Exchange JASDAQ Growth Market, raising an additional $83 MM. Under...

Joined the Piramal Group in 2005. Currently, the Senior Group Leader and Head – Discovery Analytical Sciences, and head of the NMR/protein NMR research facility. Working on protein-drug interaction studies by NMR and understanding the structure, conformation and dynamics of the target proteins. Other areas involve, ligand screening and lead...

Dr. Kevin Tan pursued his PhD at the Department of Microbiology NUS and his postdoctoral studies at the Laboratory of Molecular Parasitology, The Rockefeller University, New York, under the supervision of Professor George Cross. Upon his return to Singapore in 2003, he began his research on protozoan cell death focusing on PCD pathways in the...

Dr. Teifel completed his doctoral thesis on the optimization of non-viral gene transfer to mammalian cells in biology and received his Dr. rer. nat. (Ph.D.) in 1996 from the Technical University of Darmstadt. After completion of his doctoral thesis, he joined Roche Diagnostics in Penzberg as a group leader „Delivery Systems / DNA delivery“ where...

Dr. Anand Tharmaratnam is Senior Vice President and Head of Asia Markets, Clinical Development for Quintiles. In this role, Dr. Tharmaratnam has responsibility for the Quintiles clinical development business across the Asia-Pacific region, including Japan. In the Asia-Pacific region alone, Quintiles has more than 25 offices and employs...

David Wadsworth carried out his Ph.D work at Imperial College, London, joining Ciba-Geigy in Basel as a Research Chemist in 1989. After taking on additional responsibilities in the area of managing external collaborations and compound acquisition, he took on an 18 month assignment at the Novartis research facility in Sydney, Australia. On...

Yuan Xu is currently the Vice President and Head of Biotherapeutics Development Unit at Novartis, GNF/NIBR. Yuan joined Novartis in 2008. Previously, Yuan has held the following positions: 2008-2011: Novartis, Global Head and Vice President of Process Sciences & Production and Basel Site Head for Novartis Biologics. 2006-2008: Amgen, first as...

Chihiro has more than 30 years of pharmaceutical industry experience and is a highly regarded individual of the industry. He has led the company’s global business expansion and managed several deals including the acquisition of OSI Pharmaceuticals and alliances with Ambit Biosciences and Medivation. Prior to his current position, Chihiro served as ...